Benzinga · Mar 4, 2026
PL
NASDAQ · PLSE
Pulse Biosciences, Inc.
Healthcare · Medical - Instruments & Supplies
$48.56
Up+$0.46 (+0.96%)
Updated Aug 28, 2026, 1:06 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 933.16M
- P/E ratio
- -13.62
- Dividend yield
- 0.00%
- 52-week range
- $12.56 – $50.90
- Volume
- 260.28K
- Avg. volume
- 185.65K
Price performance
PLSE price history
1M range · 21 trading sessions · Daily adjusted prices
PLSE closed at $48.56 after 21 trading sessions, up 38.58% for the selected period.
- Last close
- $48.56
- Period change
- +38.58%
- Period low
- $35.04
- Period high
- $50.42
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $47.73 | $49.95 | $47.55 | $48.56 | 260.28K |
| Aug 26, 2026 | $49.00 | $49.7399 | $47.925 | $48.10 | 270.31K |
| Aug 25, 2026 | $49.73 | $50.90 | $47.65 | $49.00 | 366.68K |
| Aug 24, 2026 | $50.34 | $50.34 | $46.34 | $49.13 | 345.89K |
| Aug 21, 2026 | $47.47 | $50.71 | $47.47 | $50.42 | 453.13K |
| Aug 20, 2026 | $46.76 | $48.5763 | $46.64 | $47.85 | 238.62K |
| Aug 19, 2026 | $46.07 | $48.84 | $46.07 | $47.02 | 420.89K |
| Aug 18, 2026 | $46.80 | $48.10 | $45.88 | $46.00 | 526.02K |
| Aug 17, 2026 | $44.50 | $46.99 | $42.70 | $46.79 | 577.08K |
| Aug 14, 2026 | $44.50 | $45.50 | $43.75 | $44.54 | 401.26K |
| Aug 13, 2026 | $43.43 | $46.97 | $43.3755 | $44.92 | 493.64K |
| Aug 12, 2026 | $44.40 | $45.00 | $42.32 | $43.32 | 335.08K |
| Aug 11, 2026 | $41.69 | $45.25 | $41.00 | $44.40 | 760.06K |
| Aug 10, 2026 | $42.77 | $44.00 | $40.68 | $41.51 | 486.7K |
| Aug 7, 2026 | $37.84 | $45.90 | $37.40 | $42.41 | 734.62K |
| Aug 6, 2026 | $37.91 | $39.12 | $37.65 | $38.24 | 267.64K |
| Aug 5, 2026 | $38.33 | $38.33 | $36.5777 | $37.90 | 225.4K |
| Aug 4, 2026 | $38.04 | $38.90 | $37.65 | $38.17 | 342.59K |
| Aug 3, 2026 | $36.00 | $38.29 | $35.13 | $37.73 | 352.34K |
| Jul 31, 2026 | $35.42 | $35.72 | $33.52 | $35.13 | 277.94K |
| Jul 30, 2026 | $34.10 | $36.00 | $33.87 | $35.04 | 323.6K |
Latest PLSE news
The latest Smart Investors Daily articles mentioning PLSE.
Stock researchCompany · Overview
PLSE research
Overview
Company profile and research snapshot.
Company profile
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Needham | Buy | — |
| Aug 10, 2026 | Canaccord Genuity | Buy | — |
| Jun 4, 2026 | Canaccord Genuity | Buy | — |
| Jul 7, 2025 | Oppenheimer | Outperform | — |
| Sep 21, 2022 | Maxim Group | Hold | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Feb 20, 2026
Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript
ChartMill · Feb 19, 2026
Pulse Biosciences Inc (NASDAQ:PLSE) Narrows Q4 Loss, Beats Revenue Estimates
Pulse Biosciences narrows Q4 losses and beats revenue estimates, advancing key clinical trials for its bioelectric cardiac ablation technology.
Benzinga · Feb 19, 2026
Pulse Biosciences May Offer Up To $59.976M Common Shares
SEC.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
